Inscripta (formerly known as Muse Biotechnology) was founded in 2015 by Andrew Garst, Ryan Gill, and Tanya Lipscomb. Following a 2021 funding round, a company spokesperson told reporters that Inscripta has no plans to go public in the near future.
Inscripta is the developer of a genomic engineering platform. Genomic engineering, more commonly known as "gene editing," is the process by which scientists can modify the genetic blueprint of a living organism. Researchers have used the process to modify yeast cells so that the organisms will produce useful byproducts such as fuel, or chemicals with medicinal applications. Inscripta has raised more than $400 million in venture capital funding from investors such as Fidelity Management, T. Rowe Price, and D1 Capital Partners. A company spokesperson declined to offer valuation figures following the 2021 funding round.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.